Critical growth-regulating pathway disrupted by gene responsible for hereditary cancer syndrome
11/06/2013
Whitehead Institute scientists report that the gene mutated in the rare hereditary disorder known as Birt-Hogg-Dubé cancer syndrome also prevents activation of mTORC1, a critical nutrient-sensing and growth-regulating cellular pathway. This is an unexpected finding, as some cancers keep this pathway turned on to fuel their unchecked growth and expansion...
Predicting tumor response to anti-angiogenic drugs
11/06/2013
Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not...
How to measure quality of life of patients suffering from thalassemia major
11/06/2013
A CHEO-led multi-site North American study, headed by Dr. Robert Klaassen, lead investigator at CHEO and associate professor in the University of Ottawa's Department of Pediatrics, has confirmed the validity and reliability of a quality of life measurement tool for children and adults with thalassemia major...
Molecular secrets of bile duct cancers
11/06/2013
A team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, Fundeni Clinical Institute (Romania) and Koen Kaen University (Thailand), have made a seminal breakthrough in understanding the molecular basis of bile duct cancer or cholangiocarcinoma, a rare but highly lethal form of liver cancer...
Implantable sensor may monitor cancer and diabetes
11/05/2013
New research details how a sensor that can be implanted under the skin for over 1 year is able to monitor inflammation and detect nitric oxide - a molecule that has been found to show disturbed levels in the presence of some cancers. This is according to a study published in the journal Nature Nanotechnology...
Simple blood test may reveal spread of melanoma
11/05/2013
A simple blood test that examines chemical alterations in a gene called TFP12 may help identify patients whose melanoma has started to spread to other parts of the body. Researchers from the University of Dundee, UK, presented the work that could lead to such a blood test at the 9th National Cancer Research Institute (NCRI) Cancer Conference in Liverpool, UK...
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL).
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab), also known as GA101, in combination with chlorambucil chemotherapy for the treatment of people with previously untreated chronic lymphocytic leukemia (CLL)...
Early study shows that two targeted drugs with chemotherapy is safe and effective in advanced NSCLC
11/05/2013
A phase II study is the first to show that adding two targeted therapy drugs to the standard chemotherapy regimen is safe and effective as first-line treatment of advanced non-small-cell lung cancer (NSCLC). The researchers found that the safety of the drugs compared well with the safety reported in studies of the targeted drugs used alone with chemotherapy...